About Careers MedBlog Contact us

Drugmaker Shire Agrees to $54-Billion Takeover from AbbVie

by Bidita Debnath on July 20, 2014 at 11:19 PM
Font : A-A+

 Drugmaker Shire Agrees to $54-Billion Takeover from AbbVie

In a deal aimed at slashing the US giant's tax bill, Shire Pharmaceuticals has accepted a 32-billion ($54-billion, 40-billion-euro) takeover bid from AbbVie, the two companies announced on Friday.

The takeover, priced with a 53.0-percent premium for Shire stock, comes after Shire, based in Ireland, reversed its opposition to a deal earlier this week.


"The boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie," the two firms said in a statement.

The offer, comprising 24.44 in cash and 0.8960 AbbVie share per Shire share, is the same as the proposal received by the group last Sunday.

The companies added that the bid was worth the equivalent of 53.19 per Shire share, which represents a premium of 53 percent to the closing share price on May 2, one day before AbbVie's initial proposal.

The deal was expected to reduce AbbVie's effective tax rate to about 13 percent by 2016, according to the statement.

In late morning London deals, Shire's share price jumped 2.21 percent to 49.12 on the capital's FTSE 100 index, which was down 0.61 percent.

AbbVie stressed that it will "maintain a strong commitment" to growing the shareholder dividend and implementing a "significant" share repurchase scheme.

Shire Pharmaceuticals, which is listed in London and New York but based in Dublin, is a specialist in drugs for the treatment of attention-deficit disorder and rare diseases.

"The transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease and multiple emerging oncology programs," the statement added.

Shire shareholders will own approximately 25 percent of the combined company following completion of the takeover.

Shire, which provides treatments in areas such as rare diseases and neuroscience and is developing products in other therapeutic areas, had previously rejected offers from AbbVie as undervaluing the company.

The group had also previously highlighted concerns over AbbVie's plans to make Britain its home base for tax purposes.

Source: AFP


Latest Lifestyle and Wellness News

Shielding Your Skin: Embracing the Power of Sunscreen for Sunlit Days
Significance of sunscreen as an essential element of skincare has experienced a significant upswing in popularity due to the deleterious effects of UV rays.
The Silent Contributor of Workplace Burnout: Influence of Personal Relationships
Impact of workplace burnout on employee performance, wellbeing, and organizational productivity is extensive, yet the role of personal relationships has been overlooked.
 Natural Herbs That Will Give You Youthful, Glowing Skin
Ayurveda offers a time-tested treatment for aging skin using natural herbs and antiquated traditions that value sustainability and might do wonders for skin health.
 Brain Protein Behind High-Salt-Induced Hypertension and Cognitive Impairment
Researchers identified two key physiological systems involved in hypertension, cognitive, and emotional impairments following high salt intake.
Defying Time: Unlocking the Secrets to Wrinkle-Free Skin
Decoding the secrets of wrinkles by knowing the causes, prevention, and expert advice.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Drugmaker Shire Agrees to $54-Billion Takeover from AbbVie Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests